We report the identification and characterization of the first supernumerary ring chromosome 10 containing a considerable proportion of 10q euchromatin by microdissection and reverse painting in a female patient presenting with short stature. Fluorescence in situ hybridization studies showed that the marker chromosome originates from chromosome 10 and includes the euchromatic bands p11.2 and q11.2. The supernumerary marker chromosome 10 was found in 14% of the peripheral blood lymphocytes analyzed. This constitutional mosaic could be confirmed in oral mucosa cells as a second cell system (16%) by interphase FISH using an alphoid centromeric probe for chromosome 10. Parental karyotypes were normal, uniparental disomy for the normal chromosomes 10 could be excluded by microsatellite analysis. The karyotype of the patient detected in peripheral blood cells can be described as mos 47,XX,+mar.rev ish r(10)(p11.2q11.2)(wcp10+,cep10+)/46,XX.   

1.
Aalfs CM, Hoovers JM, Nieste-Otter MA, Mannens MM, Hennekam RC, Leschot NJ: Further delineation of the partial proximal trisomy 10q syndrome. J Med Genet 32:968–971 (1995).
2.
Anderlid BM, Sahlen S, Schoumans J, Holmberg E, Ahsgren I, Mortier G, Speleman F, Blennow E: Detailed characterization of 12 supernumerary ring chromosomes using micro-FISH and search for uniparental disomy. Am J Med Genet 99:223–233 (2001).
3.
Berend SA, Shaffer LG, Bejjani BA: Pure trisomy 10p involving an isochromosome 10p. Clin Genet 55:367–371 (1999).
4.
Blennow E, Tillberg E: Small extra ring chromosome derived from chromosome 10p: Clinical report and characterisation by FISH. J Med Genet 33:399–402 (1996).
5.
Blennow E, Bui TH, Kristoffersson U, Vujic M, Anneren G, Holmberg E, Nordenskjold M: Swedish survey on extra structurally abnormal chromosomes in 39 105 consecutive prenatal diagnoses: prevalence and characterization by fluorescence in situ hybridization. Prenat Diagn 14:1019–1028 (1994).
6.
Buckton KE, Spowart G, Newton MS, Evans HJ: Forty four probands with an additional “marker” chromosome. Hum Genet 69:353–370 (1985).
7.
Chen Z, Meloni-Ehrig A, Palumbos JC, Guan XY, Carroll KL, Dent KM, Carey JC: Pure trisomy 10p resulting from an extra ring chromosome: characterization by methods of advanced molecular cytogenetics. Am J Med Genet 102:379–382 (2001).
8.
Clement SJ, Leppig KA, Jarvik GP, Kapur RP, Norwood TH: Trisomy 10p: report of an unusual mechanism of formation and critical evaluation of the clinical phenotype. Am J Med Genet 65:197–204 (1996).
9.
Crolla JA, Long F, Rivera H, Dennis NR: FISH and molecular study of autosomal supernumerary marker chromosomes excluding those derived from chromosomes 15 and 22: I. Results of 26 new cases. Am J Med Genet 75:355–366 (1998).
10.
Friedrich U, Houman M, Hansen BH, Kaltoft K: Microdissection and reverse painting in a melanoma cell line: a detailed description of structurally abnormal chromosomes. Cancer Genet Cytogenet 125:5–9 (2001).
11.
Fryns JP, Kleczkowska A, Igodt-Ameye L, Van den Berghe H: Proximal duplication of the long arm of chromosome 10 (10q11.2→10q22): a distinct clinical entity. Clin Genet 32:61–65 (1987).
12.
Levy B, Papenhausen P, Tepperberg J, Dunn T, Fallet S, Magid M, Kardon N, Hirschhorn K, Warburton P: Prenatal molecular cytogenetic diagnosis of partial tetrasomy 10p due to neocentromere formation in an inversion duplication analphoid marker chromosome. Cytogenet Cell Genet 91:165–170 (2000).
13.
Nucaro A, Faedda A, Cao A, Boccone L: Partial proximal trisomy 10q syndrome: a new case. Genet Couns 13:411–416 (2002).
14.
Schinzel A: Catalogue of Unbalanced Chromosome Aberrations in Man, ed 2. (De Gruyter, Berlin, New York 2001).
15.
Schlegel M, Baumer A, Riegel M, Wiedemann U, Schinzel A: Maternal uniparental isodisomy 10 and mosaicism for an additional marker chromosome derived from the paternal chromosome 10 in a fetus. Prenat Diagn 22:418–421 (2002).
16.
Snyder FF, Lin CC, Rudd NL, Shearer JE, Heikkila EM, Hoo JJ: A de novo case of trisomy 10p: gene dosage studies of hexokinase, inorganic pyrophosphatase and adenosine kinase. Hum Genet 67:187–189 (1984).
17.
Starke H, Nietzel A, Weise A, Heller A, Mrasek K, Belitz B, Kelbova C, Volleth M, Albrecht B, Mitulla B, Trappe R, Bartels I, Adolph S, Dufke A, Singer S, Stumm M, Wegner RD, Seidel J, Schmidt A, Kuechler A, Schreyer I, Claussen U, von Eggeling F, Liehr T: Small supernumerary marker chromosomes (SMCs): genotype-phenotype correlation and classification. Hum Genet 114:51–67 (2003).
18.
Stengel-Rutkowski S, Murken JD, Frankenberger R, Riechert M, Spiess H, Rodewald A, Stene J: New chromosomal dysmorphic syndromes. 2. Trisomy 10p. Eur J Pediatr 126:109–125 (1977).
19.
Tönnies H, Neumann LM, Grüneberg B, Neitzel H: Characterization of a supernumerary ring chromosome 1 mosaicism in two cell systems by molecular cytogenetic techniques and review of the literature. Am J Med Genet 121A:163–167 (2003a).
20.
Tönnies H, Hennies HC, Spohr HL, Neitzel H: Characterization of the first supernumerary tricentric ring chromosome 1 mosaicism by conventional and molecular cytogenetic techniques. Cytogenet Genome Res 103:28–33 (2003b).
21.
Yunis E, Torres de Caballero O: Duplication deficiency as the result of meiotic segregation of a maternal inv (10). Hum Genet 57:71–74 (1981).
© 2005 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.